Clementia Pharmaceuticals Inc. clinical trials
Acquired by Ipsen, Apr 18, 2019 · source ↗
The registry lists 10 studies whose lead sponsor is Clementia Pharmaceuticals Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Apr 24, 2026.
Before and after it joined Ipsen
- First submitted before Clementia Pharmaceuticals Inc. became part of Ipsen
- 6
- First submitted after Clementia Pharmaceuticals Inc. became part of Ipsen
- 4
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Clementia Pharmaceuticals Inc.10 studies
Something wrong with this grouping? Tell us on the Ipsen page.
Studies
Recruiting first, then most recently updated. Showing 10 of 10. All Ipsen studies →
- A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP).TerminatedNCT05039515Phase 2
Sponsor listed in the registry: Clementia Pharmaceuticals Inc. · First submitted after Clementia Pharmaceuticals Inc. became part of Ipsen
- An Open-Label Extension Study of Palovarotene Treatment in Fibrodysplasia Ossificans Progressiva (FOP)CompletedNCT02279095Phase 2
Sponsor listed in the registry: Clementia Pharmaceuticals Inc. · First submitted before Clementia Pharmaceuticals Inc. became part of Ipsen
- An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva.CompletedNCT03312634Phase 3
Sponsor listed in the registry: Clementia Pharmaceuticals Inc. · First submitted before Clementia Pharmaceuticals Inc. became part of Ipsen
- An Efficacy and Safety Study of Palovarotene for the Treatment of MOTerminatedNCT03442985Phase 2
Sponsor listed in the registry: Clementia Pharmaceuticals Inc. · First submitted before Clementia Pharmaceuticals Inc. became part of Ipsen
- Study Evaluating the Effect of Food on the Pharmacokinetics of Palovarotene and the Effect of Palovarotene on the Pharmacokinetics of the CYP3A4 Substrate Midazolam in Two Cohorts of Healthy Adult SubjectsCompletedNCT04829773Phase 1
Sponsor listed in the registry: Clementia Pharmaceuticals Inc. · First submitted after Clementia Pharmaceuticals Inc. became part of Ipsen
- Study to Compare the Pharmacokinetics, Safety, and Tolerability Following Administration of Palovarotene in Healthy Japanese and Non-Asian SubjectsCompletedNCT04829786Phase 1
Sponsor listed in the registry: Clementia Pharmaceuticals Inc. · First submitted after Clementia Pharmaceuticals Inc. became part of Ipsen
- Study to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Palovarotene Ophthalmic Solution in Healthy Adult SubjectsCompletedNCT04762355Phase 1
Sponsor listed in the registry: Clementia Pharmaceuticals Inc. · First submitted after Clementia Pharmaceuticals Inc. became part of Ipsen
- An Efficacy and Safety Study of Palovarotene to Treat Preosseous Flare-ups in FOP SubjectsCompletedNCT02190747Phase 2
Sponsor listed in the registry: Clementia Pharmaceuticals Inc. · First submitted before Clementia Pharmaceuticals Inc. became part of Ipsen
- In-Home Evaluation of Episodic Administration of Palovarotene in Fibrodysplasia Ossificans Progressiva (FOP) SubjectsTerminatedNCT02521792Phase 2
Sponsor listed in the registry: Clementia Pharmaceuticals Inc. · First submitted before Clementia Pharmaceuticals Inc. became part of Ipsen
- A Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP)CompletedNCT02322255
Sponsor listed in the registry: Clementia Pharmaceuticals Inc. · First submitted before Clementia Pharmaceuticals Inc. became part of Ipsen